Skip to main content

Clover Health Unveils Counterpart Assistant Adoption

Tipranks - Thu Dec 11, 2025

Claim 50% Off TipRanks Premium and Invest with Confidence

The latest announcement is out from Clover Health Investments ( (CLOV) ).

On December 10, 2025, Clover Health Investments announced the performance outcomes of its subsidiary, Counterpart Health, Inc., and the adoption of its Counterpart Assistant technology by third-party customer clinicians. This development highlights the company’s strategic efforts to expand its technology solutions in the healthcare sector, particularly for Medicare-eligible populations, potentially impacting its market position and stakeholder interests.

The most recent analyst rating on (CLOV) stock is a Buy with a $3.70 price target. To see the full list of analyst forecasts on Clover Health Investments stock, see the CLOV Stock Forecast page.

Spark’s Take on CLOV Stock

According to Spark, TipRanks’ AI Analyst, CLOV is a Neutral.

Clover Health’s stock score is influenced by its ongoing financial challenges, despite positive developments in operational metrics and an encouraging earnings call. The financial performance remains a significant concern due to negative margins and revenue decline. Technical indicators signal potential weakness, while valuation remains unattractive due to losses. The company’s achievements in profitability and membership growth offer potential for future improvement.

To see Spark’s full report on CLOV stock, click here.

More about Clover Health Investments

Clover Health Investments, Corp. operates in the healthcare industry, focusing on providing technology-driven solutions to enhance healthcare services. The company offers the Clover Assistant technology, which is a software as a service platform designed to support payors and providers serving the Medicare eligible population.

Average Trading Volume: 8,833,065

Technical Sentiment Signal: Sell

Current Market Cap: $1.32B

For detailed information about CLOV stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.